Ikozvino mishonga inorwisa mabhakitiriya inoshandiswa mukurapa kwekiriniki, pamusoro pekutapudza hutachiona hwehutachiona hunokuvadzawo hutachiona hune hutano huri mumatumbu. Iko kukanganisa mugut microbiome ine chepfu mhedzisiro pachiropa, itsvo uye dzimwe nhengo. Iyi inyaya inofanirwa kugadziriswa. Vatsvagiri vakawana lolamicin, mushonga unorwisa mabhakitiriya uyo wakawanikwa uchishanda kurwisa hutachiona hwe gram-negative pasina kukanganisa hutano gut microbiome mune pre-kiriniki zvidzidzo. Uhu humbowo-hwe-pfungwa yekuti mishonga inorwisa mabhakitiriya inouraya hutachiona hwepathogenic ichichengetedza mabhakitiriya anobatsira mumatumbu anogona kugadzirwa kuzvirwere zve gram-negative. Inopa tariro yekugadzirisa matambudziko ane chekuita nekusarura kutariswa kwe gram-negative bacteria. Zvisinei, makore ekuwedzera tsvakurudzo anodiwa isati yasvika padanho rekushandiswa kwekliniki.
Most mishonga tarisa chete giremu-positive mabhakitiriya kana kunanga ese mabhakitiriya egiremu uye giramu-negative. Vamwe mishonga zvakananga kune giremu-negative mabhakitiriya (mabhakitiriya ane giremu-negative ane denderedzwa rekudzivirira musero ravo remadziro izvo zvinoita kuti zviome kuuraya) zvinourayawo mabhakitiriya anobatsira egiremu ari muura. Izvo zvinovhiringika mugut microbiome zvinogadzirwa zvinoonekwa zvine chepfu/yakaipa mhedzisiro kunyanya pachiropa neitsvo. Saka kudikanwa kwekugadzira mishonga inorwisa mabhakitiriya inogona kusarudza kuuraya mabhakitiriya epathogenic asi achichengetedza anobatsira. Sezvakataurwa mubepa rekutsvagisa richangoburwa, masayendisiti akagadzira imwe mishonga inorwisa mabhakitiriya inonzi lolamicin iyo yakawanikwa ichinangana ne gram-negative pathogenic bacteria asi ichichengeta anobatsira.
Lolamicin inhibitor yeLol (localization ye lipoproteins) nzira, iyo lipoprotein-transport system inowanikwa chete mu gram-negative mabhakitiriya ane maitiro akasiyana mune pathogenic uye anobatsira mabhakitiriya.
Mumasero etsika, yakanga isina mhedzisiro inonzwisisika pamabhakitiriya egiramu-positive. Pamwero wepamusoro, wakaderedza kusvika ku90% yeE. coli isingaragi zvinodhaka, K. pneumoniae uye E. cloacae Clinical isolates.
Kudzorwa nemuromo kweLolamicin kumakonzo ane septicemia isingaurayiwi nemishonga kana mabayo kwakanunura 100% yemakonzo ane septicemia uye 70% yemakonzo ane mabayo. Kupfuurirazve, lolamicin manejimendi haina kutungamira kune chero shanduko yakakura mukuumbwa kwetaxonomic yebhakitiriya mugut microbiome yemakonzo panguva yekurapa kwemazuva matatu kana kupora kwemazuva makumi maviri nemasere.
Iyi mibairo yezvidzidzo zvemhuka zvisati zvaitika zvinokurudzira uye zvinopa tariro yekugadzirisa matambudziko ane chekuita nekunangwa kusingasaruri kwe gram-negative bacteria. Icho chiratidzo chepfungwa yekuti zvinokwanisika kukudziridza mishonga iyo inosarudza inonangana inokuvadza giramu-negative mabhakitiriya uku ichichengetedza gut microbiome chero ipi zvayo yakaipa mhedzisiro. Nekudaro, makore ekumwe tsvagiridzo anodiwa kuwedzera zvakawanikwa.
***
References:
- Muñoz, KA, Ulrich, RJ, Vasan, AK et al. A Gram-negative-selective antibiotic inochengetedza gut microbiome. Zvisikwa 630, 429–436 (2024). Rakabudiswa: 29 May 2024. DOI: https://doi.org/10.1038/s41586-024-07502-0
- University of Illinois Urbana-Champaign 2024. Nhau dzekutsvagisa - Mushonga mutsva unouraya utachiona hwepathogenic, unochengetedza hutano hwehutumbu. Yakatumirwa 29 May 2024. Inowanikwa pa https://news.illinois.edu/view/6367/668002791
***